ICON Public (ICLR) Scheduled to Post Earnings on Wednesday

ICON Public (NASDAQ:ICLR) is scheduled to release its earnings data after the market closes on Wednesday, October 23rd. Analysts expect ICON Public to post earnings of $3.72 per share for the quarter. ICON Public has set its FY24 guidance at $15.00-$15.20 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, beating the consensus estimate of $3.68 by $0.07. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The firm had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same period in the prior year, the company earned $2.96 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. On average, analysts expect ICON Public to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

ICON Public Stock Down 0.6 %

NASDAQ ICLR opened at $294.87 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. The business has a fifty day moving average price of $304.63 and a 200 day moving average price of $312.85. The company has a market cap of $24.33 billion, a P/E ratio of 35.87, a P/E/G ratio of 1.35 and a beta of 1.22. ICON Public has a one year low of $221.20 and a one year high of $347.72.

Analyst Ratings Changes

ICLR has been the subject of several analyst reports. Leerink Partners initiated coverage on ICON Public in a report on Wednesday, September 18th. They issued an “outperform” rating and a $379.00 target price for the company. Robert W. Baird dropped their target price on ICON Public from $368.00 to $340.00 and set an “outperform” rating for the company in a report on Friday, September 20th. Barclays dropped their target price on ICON Public from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday. Evercore ISI dropped their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Truist Financial dropped their target price on ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a report on Monday. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $346.09.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.